ICCC Q2 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+54.9% YoY

Gross Profit

$1M22.5% margin

Operating Income

-$1M-25.3% margin

Net Income

-$2M-28.0% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-24.6%

Cash Flow

Operating Cash Flow

$581,780

Free Cash Flow

$471,039

Stock-Based Comp.

$98,021

Balance Sheet

Total Assets

$42M

Total Liabilities

$18M

Stockholders' Equity

$23M

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+54.9%
Gross Profit	$1M	$1M	+17.9%
Operating Income	-$1M	-$1M	-6.3%
Net Income	-$2M	-$1M	-11.0%

Geographic Segments

UNITED STATES

$5M100%